The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Fri., Dec. 3, 4:52 PM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #90. Imprimis Pharmaceuticals, Inc. Intellectual Property Assets from Buderer Drug Company

Acquirer: Imprimis Pharmaceuticals, Inc. (IMMY)
Acquiree: Intellectual Property Assets from Buderer Drug Company
Details: Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) today announced it has completed the acquisition of intellectual property (IP) rights related to certain proprietary innovations from the compounding pharmacy operations of Ohio-based Buderer Drug Company. The acquisition allows Imprimis to pursue the commercial development of these proprietary innovations and also provides Imprimis with a right of first refusal on additional Buderer Drug Company intellectual property and drug development opportunities.

Imprimis Pharmaceuticals is an ophthalmology-focused pharmaceutical company focused on the development, production and sale of medications. Co. operates its business through several subsidiaries: ImprimisRx, an ophthalmology focused compounding business; Park Compounding, a custom compounding business focused on patient specific orders; and Surface Pharmaceuticals, Inc., an ocular surface disease-focused 505(b)(2) specialty pharmaceutical subsidiary.

Open the IMMY Page at The Online Investor »

Company Name: 
Harrow Health Inc
Website: 
www.imprimispharma.com
Sector: 
Drugs & Pharmaceuticals
 

Open the IMMY Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree IMMY Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (4.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 90 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.